Tamer M Shaker1, Chloe Chung2, Manish K Varma3, Michael G Doherty3, Andrea M Wolf4, Mathew H Chung4, M Mura Assifi5. 1. Spectrum Health, General Surgery Residency Program, Grand Rapids, MI, USA; Department of Surgery, Michigan State University College of Human Medicine, Grand Rapids, MI, USA. 2. University of Michigan, Ann Arbor, MI, USA. 3. Advanced Radiology Services PC, Department of Radiology, Grand Rapids, MI, USA. 4. Spectrum Health, General Surgery Residency Program, Grand Rapids, MI, USA; Department of Surgery, Michigan State University College of Human Medicine, Grand Rapids, MI, USA; Division of Surgical Oncology, Spectrum Health Medical Group, Grand Rapids, MI, USA. 5. Spectrum Health, General Surgery Residency Program, Grand Rapids, MI, USA; Department of Surgery, Michigan State University College of Human Medicine, Grand Rapids, MI, USA; Division of Surgical Oncology, Spectrum Health Medical Group, Grand Rapids, MI, USA. Electronic address: Mura.Assifi@spectrumhealth.org.
Abstract
BACKGROUND: Selective internal radiation therapy (SIRT) with Ytrrium-90 (Y-90) has been used to treat hepatic malignancies with success. This study focuses on the efficacy and safety of Y-90 in the treatment of unresectable and metastatic intrahepatic cholangiocarcinoma (ICC). METHODS: A single-institution retrospective case review was performed for patients with unresectable and metastatic ICC treated with Y-90 between 2006 and 2016. RESULTS: Seventeen patients with ICC underwent 21 Y-90 treatments. Four patients had undergone prior liver resection, and six patients had extrahepatic disease at the time of treatment. Five year overall survival was 26.8%, with a median survival of 33.6 months. One patient underwent margin negative liver resection after a single treatment. Complications were appreciated in two cases. Ninety-day mortality was 0%. CONCLUSION: Treatment of ICC using Y-90 is a safe and promising procedure. Further research is needed to clarify its role in the treatment of unresectable and metastatic ICC.
BACKGROUND: Selective internal radiation therapy (SIRT) with Ytrrium-90 (Y-90) has been used to treat hepatic malignancies with success. This study focuses on the efficacy and safety of Y-90 in the treatment of unresectable and metastatic intrahepatic cholangiocarcinoma (ICC). METHODS: A single-institution retrospective case review was performed for patients with unresectable and metastatic ICC treated with Y-90 between 2006 and 2016. RESULTS: Seventeen patients with ICC underwent 21 Y-90 treatments. Four patients had undergone prior liver resection, and six patients had extrahepatic disease at the time of treatment. Five year overall survival was 26.8%, with a median survival of 33.6 months. One patient underwent margin negative liver resection after a single treatment. Complications were appreciated in two cases. Ninety-day mortality was 0%. CONCLUSION: Treatment of ICC using Y-90 is a safe and promising procedure. Further research is needed to clarify its role in the treatment of unresectable and metastatic ICC.
Authors: Premsai Kumar; Rahul Mhaskar; Richard Kim; Daniel Anaya; Jessica Frakes; Sarah Hoffe; Junsung Choi; Bela Kis Journal: J Clin Exp Hepatol Date: 2022-04-01
Authors: Felix Hahn; Lukas Müller; Aline Mähringer-Kunz; Yasemin Tanyildizi; Daniel Pinto Dos Santos; Christoph Düber; Peter R Galle; Arndt Weinmann; Roman Kloeckner Journal: J Oncol Date: 2020-10-10 Impact factor: 4.375
Authors: Héloïse Bourien; Xavier Palard; Yan Rolland; Fanny Le Du; Luc Beuzit; Thomas Uguen; Samuel Le Sourd; Marc Pracht; Vincent Manceau; Astrid Lièvre; Karim Boudjema; Etienne Garin; Julien Edeline Journal: Eur J Nucl Med Mol Imaging Date: 2018-10-29 Impact factor: 9.236
Authors: Matthias P Fabritius; Najib Ben Khaled; Wolfgang G Kunz; Jens Ricke; Max Seidensticker Journal: J Clin Med Date: 2021-11-26 Impact factor: 4.241